Topics

Human medicines European public assessment report (EPAR): Tremfya, guselkumab, Psoriasis, Date of authorisation: 10/11/2017, Revision: 3, Status: Authorised

11:32 EDT 28 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Tremfya, guselkumab, Psoriasis, Date of authorisation: 10/11/2017, Revision: 3, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Tremfya, guselkumab, Psoriasis, Date of authorisation: 10/11/2017, Revision: 3, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Tremfya, guselkumab, Psoriasis, Date of authorisation: 10/11/2017, Revision: 3, Status: Authorised"

Quick Search

Relevant Topic

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...